AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9046509 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month follow-up MRI
Number of subjects: 30
Study 1951149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement given twice a day providing an average of 10.66 kJ (400 kcal) and 5 g protein/d.
Number of subjects: 113
Study 1951149 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary supplement).
Number of subjects: 113
Study 6678543 — intervention group
Group type: EXPERIMENTAL
Intervention: Undrained cholecystectomy
Number of subjects: 123
Study 6678543 — intervention group
Group type: COMPARATOR
Intervention: Drained cholecystectomy
Number of subjects: 123
Study 31561118 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive sit‐to‐stand task (RSTS)
Number of subjects: 24
Study 31561118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental tasks
Number of subjects: 24
Study 31561118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigability (general)
Number of subjects: 24
Study 29228147 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (33.0°C) for 48 hours
Number of subjects: 292
Study 29228147 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic normothermia (36.8°C) for 48 hours
Number of subjects: 292
Study 28969313 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS-based 'patient-specific' algorithm with restrictive red cell transfusion threshold (haematocrit 18%)
Number of subjects: 204
Study 28969313 — intervention group
Group type: COMPARATOR
Intervention: Generic non-NIRS-based algorithm (standard care)
Number of subjects: 204
Study 26247967 — intervention group
Group type: COMPARATOR
Intervention: n-3 fatty acid supplementation (EPA + DHA) at varying doses (Study 1: 0, 300, 600, 900, and 1800 mg/day; Study 2: 0, 850, and 3400 mg/day)
Number of subjects: 143
Study 24284085 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA‐induced fluorescence
Number of subjects: 20
Study 24284085 — intervention group
Group type: COMPARATOR
Intervention: Enhanced MRI
Number of subjects: 20
Study 24284085 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence and spectroscopy techniques
Number of subjects: 20
Study 21415722 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 pps TENS
Number of subjects: 48
Study 21415722 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 pps TENS
Number of subjects: 48
Study 21415722 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 48
Study 17611715 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel alone (total cumulative dose range: 950‐2,475 mg/m2)
Number of subjects: 2
Study 17611715 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and adriamycin (total cumulative dose range: 700‐2,800 mg/m2)
Number of subjects: 2
Study 16553681 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training
Number of subjects: 93
Study 16553681 — intervention group
Group type: COMPARATOR
Intervention: Laughter therapy
Number of subjects: 93
Study 16553681 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 93
Study 14610097 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 meq/d salt diet
Number of subjects: 199
Study 14610097 — intervention group
Group type: COMPARATOR
Intervention: >200 meq/d salt diet
Number of subjects: 199
Study 14610097 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt sensitivity (SS)
Number of subjects: 199
Study 14610097 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt resistance
Number of subjects: 199
Study 14610097 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte cations (Na+i, Ca2+i)
Number of subjects: 199
Study 14610097 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium pump activity
Number of subjects: 199
Study 11100279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, metronidazole, and fluconazole
Number of subjects: 134
Study 11100279 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin and fluconazole
Number of subjects: 134
Study 8821692 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil sterile powder (Caverject) 5 micrograms
Number of subjects: 45
Study 8821692 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil sterile powder (Caverject) 10 micrograms
Number of subjects: 45
Study 8821692 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil sterile powder (Caverject) 20 micrograms (open fashion)
Number of subjects: 45
Study 8821692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 7698890 — intervention group
Group type: EXPERIMENTAL
Intervention: dexamethasone
Number of subjects: 19
Study 7698890 — intervention group
Group type: EXPERIMENTAL
Intervention: high‐dose methylprednisolone
Number of subjects: 19
Study 7698890 — intervention group
Group type: EXPERIMENTAL
Intervention: low‐dose methylprednisolone
Number of subjects: 19
Study 3661613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g)
Number of subjects: 8
Study 3661613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3661613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g) with indomethacin (50 mg) pretreatment
Number of subjects: 8
Study 3661613 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (50 mg) pretreatment
Number of subjects: 8
Study 29106749 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment simultaneous to periodontal treatment
Number of subjects: 50
Study 29106749 — intervention group
Group type: COMPARATOR
Intervention: Cause-related periodontal treatment before orthodontic treatment (Control)
Number of subjects: 50
Study 29106749 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 27380647 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient storytelling DVD intervention
Number of subjects: 208
Study 27380647 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient storytelling DVD intervention (for 54% of patients who watched the DVD)
Number of subjects: 208
Study 27380647 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 208
Study 23959960 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro
Number of subjects: 1525
Study 24373032 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM)
Number of subjects: 61
Study 24373032 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) + Immunoglobulin (IVIG)
Number of subjects: 61
Study 22416849 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV; TMC278) 25 mg once a day
Number of subjects: 1368
Study 22416849 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) 600 mg once a day
Number of subjects: 1368
Study 17921372 — intervention group
Group type: COMPARATOR
Intervention: Eucaloric energy intake
Number of subjects: 25
Study 17921372 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% overfeeding
Number of subjects: 25
Study 16182355 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement (ME; Motivational Interviewing + Carbon Monoxide Feedback)
Number of subjects: 273
Study 16182355 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (AHCPR Guidelines for smoking cessation)
Number of subjects: 273
Study 12153067 — intervention group
Group type: EXPERIMENTAL
Intervention: Recoded ICD‐9‐CM data
Number of subjects: 991
Study 12153067 — intervention group
Group type: COMPARATOR
Intervention: Hospital‐reported ICD‐9‐CM data
Number of subjects: 991
Study 10408488 — intervention group
Group type: EXPERIMENTAL
Intervention: P. acnes
Number of subjects: 15
Study 10408488 — intervention group
Group type: EXPERIMENTAL
Intervention: M. tuberculosis
Number of subjects: 15
Study 10408488 — intervention group
Group type: EXPERIMENTAL
Intervention: P. granulosum
Number of subjects: 15
Study 8979541 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 0
Study 8979541 — intervention group
Group type: COMPARATOR
Intervention: Control product
Number of subjects: 0
Study 1447645 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP‐Ac vaccine
Number of subjects: 162
Study 1447645 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell vaccine
Number of subjects: 162
Study 3882109 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine
Number of subjects: 30
Study 3882109 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 30
Study 3882109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30904691 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-TNS (transcutaneous trigeminal nerve stimulation)
Number of subjects: 29
Study 30904691 — intervention group
Group type: COMPARATOR
Intervention: Sham-TNS (control group)
Number of subjects: 29
Study 30904691 — intervention group
Group type: EXPERIMENTAL
Intervention: Median Nerve Stimulation (MNS)
Number of subjects: 29
Study 30152167 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-adaptive randomization procedure based on Mann-Whitney U test statistic
Number of subjects: 0
Study 30152167 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed procedure
Number of subjects: 0
Study 26667034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis (450 μg/kg THC)
Number of subjects: 122
Study 26667034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine HCl (300 mg)
Number of subjects: 122
Study 26667034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 26667034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis and Cocaine
Number of subjects: 122
Study 24767620 — intervention group
Group type: EXPERIMENTAL
Intervention: CI Compassionate Goals
Number of subjects: 54
Study 24767620 — intervention group
Group type: EXPERIMENTAL
Intervention: CI Coping
Number of subjects: 54
Study 24767620 — intervention group
Group type: COMPARATOR
Intervention: Standard TSST instructions (SI)
Number of subjects: 54
Study 24767620 — intervention group
Group type: COMPARATOR
Intervention: Standard instructions with access to 'control' (SI Control)
Number of subjects: 54
Study 23106987 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimanual constraint‐induced movement therapy (CIMT)
Number of subjects: 16
Study 23106987 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand‐arm bimanual intensive training (HABIT)
Number of subjects: 16
Study 20600472 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS (15 Hz)
Number of subjects: 34
Study 20600472 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 34
Study 18046973 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril 30 mg once daily (titration 60 mg od)
Number of subjects: 375
Study 18046973 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg once daily (titration 100 mg od)
Number of subjects: 375
Study 18046973 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP assessments
Number of subjects: 375
Study 18046973 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to study medications
Number of subjects: 375
Study 16128599 — intervention group
Group type: EXPERIMENTAL
Intervention: MF 5232 (Mucotrol)
Number of subjects: 30
Study 16128599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12522468 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg
Number of subjects: 441
Study 12522468 — intervention group
Group type: COMPARATOR
Intervention: perindopril 4 mg
Number of subjects: 441
Study 12522468 — intervention group
Group type: EXPERIMENTAL
Intervention: SBPM
Number of subjects: 441
Study 12522468 — intervention group
Group type: EXPERIMENTAL
Intervention: office hypertension
Number of subjects: 441
Study 12522468 — intervention group
Group type: EXPERIMENTAL
Intervention: home hypertension
Number of subjects: 441
Study 10547552 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (50 mg every other day)
Number of subjects: 22071
Study 10547552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study 8697725 — intervention group
Group type: EXPERIMENTAL
Intervention: ELAT
Number of subjects: 147
Study 8697725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube DAT
Number of subjects: 147
Study 8697725 — intervention group
Group type: COMPARATOR
Intervention: Gel-DAT
Number of subjects: 147
Study 1576632 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (I-C)
Number of subjects: 117
Study 1576632 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin and aminoglycoside (C+A)
Number of subjects: 117
Study 6203312 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term anthralin application schedule
Number of subjects: 63
Study 6203312 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthralin treatment once or twice a week after healing
Number of subjects: 63
Study 6203312 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthralin treatment combined with UV irradiation
Number of subjects: 63
Study 6203312 — intervention group
Group type: COMPARATOR
Intervention: Anthralin treatment
Number of subjects: 63
Study 30461111 — intervention group
Group type: EXPERIMENTAL
Intervention: Care as usual plus SOS training (n = 125)
Number of subjects: 250
Study 30461111 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (n = 125)
Number of subjects: 250
Study 29513699 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebos without deception
Number of subjects: 46
Study 29513699 — intervention group
Group type: EXPERIMENTAL
Intervention: Inducing positive expectations about the placebo effect
Number of subjects: 46
Study 29513699 — intervention group
Group type: COMPARATOR
Intervention: No pills at all (Control)
Number of subjects: 46
Study 26391889 — intervention group
Group type: EXPERIMENTAL
Intervention: SKILLS intervention
Number of subjects: 137
Study 26391889 — intervention group
Group type: EXPERIMENTAL
Intervention: ENGAGE intervention
Number of subjects: 137
Study 25269854 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine HCl ophthalmic solution 0.1%
Number of subjects: 50
Study 25269854 — intervention group
Group type: COMPARATOR
Intervention: Epinastine HCl ophthalmic solution 0.05%
Number of subjects: 50
Study 22101494 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised stress‐induction protocol (Trier Social Stress Test)
Number of subjects: 48
Study 22101494 — intervention group
Group type: COMPARATOR
Intervention: Standardised control situation
Number of subjects: 48
Study 20560910 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-specific IgE levels for cockroach
Number of subjects: 546
Study 20560910 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-specific IgE levels for dust mite
Number of subjects: 546
Study 20560910 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-specific IgE levels for mouse
Number of subjects: 546
Study 20560910 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-specific IgE levels for cat
Number of subjects: 546
Study 20560910 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cat, dust mite, and mouse allergen-specific IgE levels
Number of subjects: 546
Study 16928710 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 56
Study 16928710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 16236859 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline 225 mg bid po for 8 weeks (group 1)
Number of subjects: 60
Study 16236859 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline 225 mg bid po for 8 weeks (group 2)
Number of subjects: 60
Study 16236859 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline 225 mg bid po for 8 weeks (both groups)
Number of subjects: 60
Study 12398955 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI risk score (scores 0 to 2)
Number of subjects: 0
Study 12398955 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI risk score (score 3)
Number of subjects: 0
Study 12398955 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI risk score (score 4)
Number of subjects: 0
Study 12398955 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI risk score (scores 5 to 7)
Number of subjects: 0
Study 12398955 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (TIMI score 0 to 2)
Number of subjects: 0
Study 12398955 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (TIMI score >= 3)
Number of subjects: 0
Study 12398955 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI risk score
Number of subjects: 0
Study 12398955 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative group
Number of subjects: 0
Study 9933750 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (EPO) 2 g/day for 6 weeks
Number of subjects: 16
Study 9933750 — intervention group
Group type: COMPARATOR
Intervention: Linoleic acid (LA) 2 g/day for 6 weeks
Number of subjects: 16
Study 7551880 — intervention group
Group type: EXPERIMENTAL
Intervention: DAN-PSS-1 system
Number of subjects: 0
Study 7551880 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy
Number of subjects: 0
Study 7551880 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-blocker treatment
Number of subjects: 0
Study 2186867 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic therapies (e.g., low-dose diuretics such as Chlorthalidone, 12.5 or 25 mg per day)
Number of subjects: 0
Study 2186867 — intervention group
Group type: COMPARATOR
Intervention: Nonpharmacologic therapy
Number of subjects: 0
Study 2186867 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic therapy
Number of subjects: 0
Study 2186867 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose diuretics
Number of subjects: 0
Study 2186867 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 0
Study 2186867 — intervention group
Group type: EXPERIMENTAL
Intervention: Other agents (beta-blockers, reserpine, ACE inhibitors, calcium channel blockers)
Number of subjects: 0
Study 355960 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous carbenicillin (administered preoperatively and continued for 24 hours)
Number of subjects: 99
Study 355960 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antibiotics (control)
Number of subjects: 99
Study 31959176 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically-tailored meals
Number of subjects: 20
Study 31959176 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically-tailored meals combined with diabetes self-management education or lifestyle interventions
Number of subjects: 20
Study 31009738 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with TB‐IRIS (n = 26)
Number of subjects: 48
Study 31009738 — intervention group
Group type: COMPARATOR
Intervention: Participants without TB‐IRIS (n = 22)
Number of subjects: 48
Study 28705307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal vibration method (using Yourtone® applied to the cervical trachea for up to 5 minutes)
Number of subjects: 12
Study 28705307 — intervention group
Group type: COMPARATOR
Intervention: Acapella method (a current oscillation device)
Number of subjects: 12
Study 28705307 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 12
Study 25887344 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine combined with dihydroartemisinin-piperaquine (three different single doses)
Number of subjects: 1200
Study 25887344 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine alone (control group)
Number of subjects: 1200
Study 25887344 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct membrane feeding experiments
Number of subjects: 1200
Study 24005210 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning module plus textbook
Number of subjects: 28
Study 24005210 — intervention group
Group type: COMPARATOR
Intervention: Textbook only (control group)
Number of subjects: 28
Study 20004499 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen treatment for 12 weeks
Number of subjects: 43
Study 20004499 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 43
Study 19880890 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial opening-wedge high tibial osteotomy fixed by TomoFix plates
Number of subjects: 42
Study 19880890 — intervention group
Group type: COMPARATOR
Intervention: Lateral closing-wedge high tibial osteotomy fixed by TomoFix plates
Number of subjects: 42
Study 16395699 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea drinkers (defined as those who consumed at least 1 cup of tea per day for at least 6 months)
Number of subjects: 2623
Study 16395699 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea drinkers (men)
Number of subjects: 2623
Study 16395699 — intervention group
Group type: COMPARATOR
Intervention: Controls (non-tea drinkers)
Number of subjects: 2623
Study 15589857 — intervention group
Group type: EXPERIMENTAL
Intervention: HMR 3339 (10 mg)
Number of subjects: 118
Study 15589857 — intervention group
Group type: EXPERIMENTAL
Intervention: HMR 3339 (50 mg)
Number of subjects: 118
Study 15589857 — intervention group
Group type: EXPERIMENTAL
Intervention: HMR 3339 (2.5 mg)
Number of subjects: 118
Study 15589857 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg)
Number of subjects: 118
Study 15589857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 11320497 — intervention group
Group type: EXPERIMENTAL
Intervention: Conductivity kinetic model in paired filtration dialysis (PFD)
Number of subjects: 0
Study 11320497 — intervention group
Group type: COMPARATOR
Intervention: Sodium kinetic model
Number of subjects: 0
Study 11320497 — intervention group
Group type: EXPERIMENTAL
Intervention: Conductivity kinetic model
Number of subjects: 0
Study 9207647 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic defibrillation thresholds
Number of subjects: 24
Study 9207647 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic defibrillation thresholds
Number of subjects: 24
Study 9207647 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock impedance
Number of subjects: 24
Study 7915625 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic beta‐adrenergic blocking therapy (study group)
Number of subjects: 40
Study 7915625 — intervention group
Group type: COMPARATOR
Intervention: No beta‐blocking therapy (control group)
Number of subjects: 40
Study 3120485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro15‐1788
Number of subjects: 57
Study 3120485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57